Insider Transactions in Q4 2024 at Syros Pharmaceuticals, Inc. (SYRS)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 02
2024
|
Nancy A Simonian |
SELL
Open market or private sale
|
Direct |
37,070
-90.26%
|
$0
$0.27 P/Share
|
|
Nov 25
2024
|
Nancy A Simonian |
SELL
Open market or private sale
|
Direct |
134,713
-76.64%
|
$0
$0.27 P/Share
|
|
Nov 19
2024
|
Gerald E Quirk Chief Legal & Compliance Offic |
SELL
Open market or private sale
|
Direct |
46,657
-100.0%
|
$0
$0.22 P/Share
|
|
Nov 18
2024
|
Jason Haas Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
137,803
-100.0%
|
$0
$0.21 P/Share
|
|
Nov 18
2024
|
Conley Chee President & CEO |
SELL
Open market or private sale
|
Direct |
134,797
-100.0%
|
$0
$0.2 P/Share
|
|
Nov 18
2024
|
David Roth Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,099
-100.0%
|
$0
$0.2 P/Share
|
|
Nov 18
2024
|
Kristin Stephens Chief Development Officer |
SELL
Open market or private sale
|
Direct |
36,133
-100.0%
|
$0
$0.22 P/Share
|
|
Oct 31
2024
|
Kristin Stephens Chief Development Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,104
-14.45%
|
$12,208
$2.09 P/Share
|
|
Oct 31
2024
|
Kristin Stephens Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+28.7%
|
-
|
|
Oct 31
2024
|
Conley Chee President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,707
-6.24%
|
$17,414
$2.09 P/Share
|
|
Oct 31
2024
|
Conley Chee President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+10.86%
|
-
|
|
Oct 31
2024
|
Jason Haas Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,624
-3.92%
|
$11,248
$2.09 P/Share
|
|
Oct 31
2024
|
Jason Haas Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+11.63%
|
-
|
|
Oct 31
2024
|
David Roth Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,776
-35.9%
|
$13,552
$2.09 P/Share
|
|
Oct 31
2024
|
David Roth Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,875
+50.0%
|
-
|
|
Oct 31
2024
|
Nancy A Simonian |
BUY
Exercise of conversion of derivative security
|
Direct |
40,125
+18.58%
|
-
|